Versant Ventures commits $30m to Matterhorn Biosciences

Versant Ventures has launched Matterhorn Biosciences AG, a biotech company focused on developing T cell receptor therapies.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this